Advertisement

Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States

Published:September 18, 2021DOI:https://doi.org/10.1016/j.jaad.2021.09.019

      Background

      Among patients in the United States with psoriasis (PsO), limited data exist on the incidence and prevalence of psoriatic arthritis (PsA) based on disease severity.

      Objective

      To assess the incidence, prevalence, and predictors of PsA among patients with PsO stratified by PsO severity using treatment type.

      Methods

      Incidence of PsA per 100 PsO patient-years (PY) and prevalence were assessed using the Optum electronic health records database. Incidence was assessed from PsO diagnosis and 1 year after PsO diagnosis overall and stratified by mutually exclusive treatment classes as a severity surrogate.

      Results

      The overall incidence of PsA was 2.9 (95% CI, 2.9-3.0) events per 100 PY. The incidence (95% CI) by severity surrogate was 2.1 (2.1-2.1), 9.9 (9.5-10.4), and 17.6 (16.9-18.3) events per 100 PY for patients with mild, moderate, and severe PsO as determined by receiving nonsystemics, nonbiologic systemic therapy, and biologics, respectively. When excluding patients diagnosed with PsA 1 year after PsO diagnosis, overall incidence was lower (1.7 [95% CI, 1.6-1.7] events per 100 PY), with similar trends for treatment-severity surrogates.

      Limitations

      Results may not be generalizable to a wider population.

      Conclusion

      The risk of developing PsA increased with disease severity and was highest in patients with the most severe PsO.

      Key words

      Abbreviations used:

      EHR (electronic health record), ICD-10-CM (International Classification of Diseases, Tenth Revision, Clinical Modification), ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification), NBST (nonbiologic systemic therapy), PsA (psoriatic arthritis), PsO (psoriasis), PY (patient-years)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ogdie A.
        • Gelfand J.M.
        Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: a review of available evidence.
        Curr Rheumatol Rep. 2015; 17: 64
        • Gladman D.D.
        Psoriatic arthritis.
        Rheum Dis Clin North Am. 1998; 24: 829-844
        • Alinaghi F.
        • Calov M.
        • Kristensen L.E.
        • et al.
        Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies.
        J Am Acad Dermatol. 2019; 80: 251-265.e19
        • Mease P.J.
        • Gladman D.D.
        • Papp K.A.
        • et al.
        Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.
        J Am Acad Dermatol. 2013; 69: 729-735
        • Eder L.
        • Haddad A.
        • Rosen C.F.
        • et al.
        The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study.
        Arthritis Rheumatol. 2016; 68: 915-923
        • Kimball A.B.
        • Guérin A.
        • Tsaneva M.
        • et al.
        Economic burden of comorbidities in patients with psoriasis is substantial.
        J Eur Acad Dermatol Venereol. 2011; 25: 157-163
        • Lee S.
        • Mendelsohn A.
        • Sarnes E.
        The burden of psoriatic arthritis: a literature review from a global health systems perspective.
        P T. 2010; 35: 680-689
        • Scher J.U.
        • Ogdie A.
        • Merola J.F.
        • Ritchlin C.
        Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition.
        Nat Rev Rheumatol. 2019; 15: 153-166
        • Ogdie A.
        • Schwartzman S.
        • Husni M.E.
        Recognizing and managing comorbidities in psoriatic arthritis.
        Curr Opin Rheumatol. 2015; 27: 118-126
        • Merola J.F.
        • Herrera V.
        • Palmer J.B.
        Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA.
        Clin Rheumatol. 2018; 37: 2751-2761
        • Ogdie A.
        • Nowell W.B.
        • Applegate E.
        • et al.
        Patient perspectives on the pathway to psoriatic arthritis diagnosis: results from a web-based survey of patients in the United States.
        BMC Rheumatol. 2020; 4: 2
        • Kirkham B.
        • de Vlam K.
        • Li W.
        • et al.
        Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.
        Clin Exp Rheumatol. 2015; 33: 11-19
        • Haroon M.
        • Gallagher P.
        • FitzGerald O.
        Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis.
        Ann Rheum Dis. 2015; 74: 1045-1050
        • Menter A.
        • Korman N.J.
        • Elmets C.A.
        • et al.
        Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
        J Am Acad Dermatol. 2009; 61: 451-485
        • Menter A.
        • Strober B.E.
        • Kaplan D.H.
        • et al.
        Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
        J Am Acad Dermatol. 2019; 80: 1029-1072
        • Gottlieb A.
        • Korman N.J.
        • Gordon K.B.
        • et al.
        Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
        J Am Acad Dermatol. 2008; 58: 851-864
        • Coates L.C.
        • Gossec L.
        • Ramiro S.
        • et al.
        New GRAPPA and EULAR recommendations for the management of psoriatic arthritis.
        Rheumatology (Oxford). 2017; 56: 1251-1253
        • Coates L.C.
        • Kavanaugh A.
        • Mease P.J.
        • et al.
        Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis.
        Arthritis Rheumatol. 2016; 68: 1060-1071
        • Murage M.J.
        • Anderson A.
        • Casso D.
        • et al.
        Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity.
        J Dermatolog Treat. 2019; 30: 141-149
      1. The great data transition. Optum.
        • Egeberg A.
        • Gyldenløve M.
        • Zachariae C.
        • Skov L.
        Validation of psoriasis severity classification based on use of topical or systemic treatment.
        J Eur Acad Dermatol Venereol. 2018; 32: e4-e5
        • Wilson F.C.
        • Icen M.
        • Crowson C.S.
        • McEvoy M.T.
        • Gabriel S.E.
        • Kremers H.M.
        Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study.
        Arthritis Rheum. 2009; 61: 233-239
        • Lindberg I.
        • Lilja M.
        • Geale K.
        • et al.
        Incidence of psoriatic arthritis in patients with skin psoriasis and associated risk factors: a retrospective population-based cohort study in Swedish routine clinical care.
        Acta Derm Venereol. 2020; 100: adv00324
        • Gisondi P.
        • Del Giglio M.
        • Girolomoni G.
        Treatment approaches to moderate to severe psoriasis.
        Int J Mol Sci. 2017; 18: 2427
        • Gladman D.D.
        • Antoni C.
        • Mease P.
        • Clegg D.O.
        • Nash P.
        Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
        Ann Rheum Dis. 2005; 64: ii14-ii17
        • Gelfand J.M.
        • Weinstein R.
        • Porter S.B.
        • Neimann A.L.
        • Berlin J.A.
        • Margolis D.J.
        Prevalence and treatment of psoriasis in the United Kingdom: a population-based study.
        Arch Dermatol. 2005; 141: 1537-1541
        • Alenius G.M.
        • Stenberg B.
        • Stenlund H.
        • Lundblad M.
        • Dahlqvist S.R.
        Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire.
        J Rheumatol. 2002; 29: 2577-2582
        • Eder L.
        • Chandran V.
        • Gladman D.D.
        What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?.
        Curr Opin Rheumatol. 2015; 27: 91-98
        • Soltani-Arabshahi R.
        • Wong B.
        • Feng B.J.
        • Goldgar D.E.
        • Duffin K.C.
        • Krueger G.G.
        Obesity in early adulthood as a risk factor for psoriatic arthritis.
        Arch Dermatol. 2010; 146: 721-726
        • Tinazzi I.
        • McGonagle D.
        • Biasi D.
        • et al.
        Preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis in patients with psoriasis.
        J Rheumatol. 2011; 38: 2691-2692
        • Tey H.L.
        • Ee H.L.
        • Tan A.S.
        • Theng T.S.
        • Wong S.N.
        • Khoo S.W.
        Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis.
        J Dermatol. 2010; 37: 426-430
        • Rouzaud M.
        • Sevrain M.
        • Villani A.P.
        • et al.
        Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review.
        J Eur Acad Dermatol Venereol. 2014; 28: 17-26
        • Egeberg A.
        • See K.
        • Garrelts A.
        • Burge R.
        Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort.
        BMC Dermatol. 2020; 20: 3
        • Haroon M.
        • Kirby B.
        • FitzGerald O.
        High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires.
        Ann Rheum Dis. 2013; 72: 736-740
        • Lebwohl M.G.
        • Kavanaugh A.
        • Armstrong A.W.
        • Van Voorhees A.S.
        US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.
        Am J Clin Dermatol. 2016; 17: 87-97
        • Kavanaugh A.
        • Helliwell P.
        • Ritchlin C.T.
        Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey.
        Rheumatol Ther. 2016; 3: 91-102